Clinical Trials Logo

Fish Allergy clinical trials

View clinical trials related to Fish Allergy.

Filter by:
  • None
  • Page 1

NCT ID: NCT05590299 Active, not recruiting - Clinical trials for Food Allergy in Children

Fish Oral Immunotherapy in Hong Kong Children

Start date: January 6, 2023
Phase: N/A
Study type: Interventional

At present there is no cure for food allergy. People with a food allergy need to avoid the food they are allergic to in order to stay safe, but we know that accidental exposure is common. Researchers have begun to look at the effectiveness of 'oral immunotherapy' as a treatment for food allergy but results have been mixed. This study is a randomized controlled trial to evaluate the effectiveness of Fish Immunotherapy (FOIT), with codfish as the primary focus, in inducing tolerance in children with fish allergy compared with Placebo. Children will take increasing doses of codfish protein until a total of 12 months treatment is completed. Children will be tested for fish allergy at the start of the study, at the end of fish treatment T1 (12 months) and T2 (8 weeks) after treatment.

NCT ID: NCT02365168 Completed - Fish Allergy Clinical Trials

Allergy Against Different Species of Fish in Children and Adolescents Allergic to Fish

TRO-FAST
Start date: September 2014
Phase: N/A
Study type: Interventional

Study hypothesis: Some children and adolescents with fish allergy can tolerate eating some species of fish Purpose of the study: The purpose of this study is to determine to which degree fish allergic children and adolescents can tolerate some species of fish and find the minimal eliciting allergen dose to which only 10% of participants get allergic reaction. Participants: Participants are 40 patients recruited from children and adolescents outpatient clinics at the University Hospital of North Norway with a history of fish allergy and sensibilisation of one or more fish species with either positive specific IgE in serum or skin prick test. Patients with sensibilisation to one or more fish species that never have eaten fish are also recruited. Method: - All participants undergo a clinical examination including lung function test with spirometry before inclusion in the study. - All participants are tested for allergic sensibilisation with measure of specific IgE against common food and inhalation allergens in addition to 10 different fish species. - All participants are challenged with cod, salmon, mackerel and placebo, disguised in a chocolate mousse. The challenges are performed in randomized order with Double Blind Placebo Controlled Food Challenge (DBPCFC) on 4 different challenge days with minimum 6 weeks in between each challenge day. - Participant with allergy to pollen will not be challenged during pollen season. - Test food is developed especially to this study in cooperation with The National Institute of Food Research in Norway and The University of Manchester. The National Institute of Food Research in Norway have produced a dried powder of cod, salmon and mackerel. The "Molecular Allergology group at Manchester Institute of Biotechnology, the University of Manchester, have produced test kits based on chocolate mousse containing low and high doses of the fish powders. The National Institute of Food Research have measured protein content and microbiology in the fish powders. The Molecular Allergology group have provided quality measurements of the final product and tested the disguise in a sensoric test panel. - Participants with no allergic reaction to one or more of the blinded challenges undergo open food challenge with larger doses of cooked fish than used in the DBPCFC, after the randomization has been broken.

NCT ID: NCT02017626 Completed - Fish Allergy Clinical Trials

FAST-Fish -Food Allergy Specific Treatment for Fish Allergy.

Start date: August 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to investigate the safety and tolerability of Subcutaneous Immunotherapy treatment (SCIT) with incremental doses of a modified recombinant fish parvalbumin (mCyp c 1) quantified in mass units: To establish a safe dose of the candidate hypo-allergen in human subjects and To study the pharmaco-dynamics of the hypo-allergen administered to human subjects. The study is performed as a placebo-controlled double-blinded randomized trial with 24 fish allergic patients allocated into three different groups of eight.